AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00022672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anastrazole (Arimidex®)
Description: 1 mg tablet taken orally daily
Study NCT00022672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrazole (Arimidex®)
Description: 1 mg tablet taken orally daily
Study NCT01619319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy
Description: auditory computer games designed to improve the speed at which people react when they hear something and at which they process that information.
Study NCT01619319 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: computer games
Description: computer games that that consist of word puzzles
Study NCT04517253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally
Study NCT04053023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2330672 (linerixibat)
Description: GSK2330672 is available as a tablet with unit dose strength of 45 mg.
Study NCT02053298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol & Dorzolamide
Description: Topical preservative-free fixed combination of timolol 0.5%+dorzolamide 2% to be applied bid for 1 month
Study NCT01332266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E7050
Description: E7050 given orally at 200, 300, or 400 mg once daily.
Study NCT03720665 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine_TMS
Description: Caffeine group: participants will receive a caffeine tablet and all electrical stimulations in a random order \[transcranial electrical stimulation (tACS 140 Hz at 1 mA, 0.4 mA, sham) and paired associative stimulation (PAS 25)\] Placebo tablet: participants will receive a placebo tablet and all electrical stimulations in a random order \[transcranial electrical stimulation (tACS 140 Hz at 1 mA, 0.4 mA, sham) and paired associative stimulation (PAS 25)\]
Study NCT01332266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab is given at an initial dose of 400 mg/m2 given as a 2-hour intravenous (IV) infusion on Day 1 of Cycle 1, followed by a dose of 250 mg/m2 given as a 1-hour IV infusion on Day 8, Day 15, and Day 22 of Cycle 1, and Day 1, Day 8, Day 15, and Day 22 of each subsequent cycle.
Study NCT03720665 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Caffeine_TMS
Description: Caffeine group: participants will receive a caffeine tablet and all electrical stimulations in a random order \[transcranial electrical stimulation (tACS 140 Hz at 1 mA, 0.4 mA, sham) and paired associative stimulation (PAS 25)\] Placebo tablet: participants will receive a placebo tablet and all electrical stimulations in a random order \[transcranial electrical stimulation (tACS 140 Hz at 1 mA, 0.4 mA, sham) and paired associative stimulation (PAS 25)\]
Study NCT01452139 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Point-of-Care Genetic Testing
Description: Point-of-Care Genetic Testing for Genetic Variants Linked to Adverse Outcomes with Clopidogrel (CYP2C19\*2 \& ABCB1 3435 TT)
Study NCT01452139 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Point-of-Care Genetic Testing
Description: Point-of-Care Genetic Testing for Genetic Variants Linked to Adverse Outcomes with Clopidogrel (CYP2C19\*2 \& ABCB1 3435 TT)
Study NCT01452139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Treatment of STEMI patients carrying at least one high risk genetic variant with prasugrel 10mg daily.
Study NCT03112746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to Daily Occupational Performance
Description: In CO-OP Approach, therapists use mediational techniques to teach cognitive strategies - GOAL, PLAN, DO, CHECK - to improve occupational performance in goals chosen by the children in collaboration with them and their parents.
Study NCT01204996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection
Description: 10 mg/kg CNTO 888 every 2 weeks plus DOXIL®/Caelyx® (doxorubicin HCl liposome injection) 50 mg/m2 every 4 weeks
Study NCT01204996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO888 + gemcitabine
Description: 15 mg/kg CNTO 888 every 3 weeks plus gemcitabine 1000 mg/m2 administered on Days 1 and 8 of the 3-week cycle
Study NCT01204996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO888 + Paclitaxel and carboplatin
Description: 15 mg/kg CNTO 888 every 3 weeks plus paclitaxel 175 mg/m2 and carboplatin dosed to AUC 6 every 3 weeks
Study NCT01204996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO888 + docetaxel
Description: 15 mg/kg CNTO 888 every 3 weeks plus docetaxel 75 mg/m2 every 3 weeks
Study NCT02136654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally tailored diabetes program
Description: Includes family member and peer support Includes communication training
Study NCT06509867 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DGG+PRF
Description: de-epithelialized subepithelial connective tissue grafts+ L-Platelet Rich Fibrin + Coronally advanced flap
Study NCT06509867 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DGG
Description: de-epithelialized subepithelial connective tissue grafts+ Coronally advanced flap
Study NCT04541199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: closed loop
Description: RR and VT will be selected according to the respiratory mechanics by closed loop algorithm
Study NCT04541199 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional
Description: RR, VT, Ti will be selected by the clinician according to the respiratory mechanics
Study NCT01179100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine (10mg/ml) Loading: 1.5 mg/kg + Infusion: 0.035 mg/kg/min
Study NCT01179100 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine (10mg/ml) Loading: 1.5 mg/kg + Infusion: 0.035 mg/kg/min
Study NCT01833598 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PNT + PRP
Description: The PNT + PRP group will undergo needle tenotomy under direct and continuous ultrasound guidance with even distribution of PRP into the peritendinous area(s) of PNT around the affected tendon.
Study NCT01833598 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PNT alone
Description: The PNT group will undergo needle tenotomy under direct and continuous ultrasound guidance local anesthesia into the affected tendon. 10 minutes after the injection, the ultrasound machine probe will be passed over the areas treated both to evaluate for any structural changes and for any complications.
Study NCT02123953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets
Study NCT02123953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-438 Placebo
Description: TAK-438 placebo-matching tablets
Study NCT03392194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep hygiene intervention
Description: The community-adapted SH intervention includes 2 group sessions. (1) teach the importance of sleep and the core components of SH; distribute and explain the daily sleep log (2) facilitate an open discussion where participants share challenges and experiences implementing a SH goal.
Study NCT03392194 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep hygiene intervention
Description: The community-adapted SH intervention includes 2 group sessions. (1) teach the importance of sleep and the core components of SH; distribute and explain the daily sleep log (2) facilitate an open discussion where participants share challenges and experiences implementing a SH goal.
Study NCT03392194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Description: Following the SH intervention, participants randomized to the SH+Y arm will participate in 8 weekly beginner level yoga classes. Classes will increase participants' skill and comfort with yoga postures and relaxing breathing exercises so that participants can adopt an evening yoga practice (10 weeks).
Study NCT01453738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ex- vivo cultured adult allogeneic MSCs
Description: Single intraarticular dose of allogeneic MSCs suspended in 2ml Plasmalyte followed by 2ml of Hyaluronan
Study NCT01453738 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Plasmalyte-A
Description: Single intraarticular dose of 2ml Plasmalyte followed by 2ml Hyaluronan
Study NCT00075387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IA
Study NCT00431054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: Loading Dose = 100 mg by mouth (PO) every 6 hours, followed by 50 mg by mouth (PO) daily
Study NCT00431054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m\^2 by vein over 1 hour every 4 weeks
Study NCT04009772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefepime
Description: Antibiotic prophylaxis
Study NCT04009772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefuroxime plus Metronidazole
Description: Antibiotic prophylaxis
Study NCT03682614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCG
Description: we will use the catheter to pass through the cervix, and after that, the experiment Group will accept 40 μl 500 IU HCG injection into the uterine cavity 2 days before the blastocyst transfer.
Study NCT03682614 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: culture medium
Description: The placebo group will accept 40 μl of culture medium injection into the uterine cavity 2 days before the blastocyst transfer.
Study NCT00075387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00075387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Phosphate
Description: Given IV
Study NCT00075387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00075387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Thiosulfate
Description: Given IV
Study NCT01363180 — intervention group
Intervention type: BEHAVIORAL
Intervention: Trier Social Stress Test (TSST)
Description: The TSST is a standardized psychological stress challenge where a participant performs a speech and mental math task in front of 3 unfamiliar individuals, in order to evoke an HPA axis stress response in a laboratory setting.
Study NCT01363180 — intervention group
Intervention type: OTHER
Intervention: No stress condition
Study NCT03424369 — intervention group
Intervention type: PROCEDURE
Intervention: Tympanoplasty
Description: Tympanoplasty
Study NCT04648670 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation
Description: The intervention was applied to the experimental group and consisted in 10 sessions of 45 minutes/week during 10 weeks. Each session included four parts: (a) Reality orientation therapy, (b) activities related to memory, orientation, language, praxis, gnosis, calculation, perception, reasoning, visual attention, and executive functions, (c) individual practical exercises and (d) correction of the practical exercises..
Study NCT00881153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefprozil 250 mg/5 ml Oral Suspension (Sandoz GmbH)
Study NCT00881153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb)
Study NCT02753621 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group singing
Description: Weekly group singing classes led by professional choir instructor, lasting 90 minutes. 12 classes over 12 consecutive weeks.
Study NCT02753621 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facilitated Discussion Group
Description: Weekly facilitated discussion group led by Parkinson Disease educator, lasting 90 minutes. 12 sessions over 12 consecutive weeks.
Study NCT00867087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inotuzumab ozogamicin (CMC-544)
Description: 1.8 mg/m\^2 every 21 days by intravenous infusion, 3 to 6 doses
Study NCT00867087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m\^2 two days before cycle 1 by intravenous infusion; 375 mg/m\^2 every 21 days by intravenous infusion, 3 to 6 doses
Study NCT02654392 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: corn syrup
Description: This group will receive an iso-energetic corn syrup supplement everyday for 5 weeks
Study NCT02654392 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Polyunsaturated fatty acid
Description: This groups will receive 4 capsules/70kg body mass (Pureform Omega® capsules made from Fax, Sunflower, Coconut, Evening Primrose, \& Pumpkin oils) every day for 5 weeks
Study NCT05164601 — intervention group
Intervention type: OTHER
Intervention: No Intervention - Observational Only
Description: Clinical Follow-Up
Study NCT03197974 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness for Bipolar
Description: Brief online self-management program with email coaching support
Study NCT03197974 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychoeducation for Bipolar
Description: Brief online self-management program with email coaching support
Study NCT02070393 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton
Description: 14-24 Radiation treatments using Protons
Study NCT04053023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic acid
Description: Obeticholic acid is available as a tablet with a unit dose strength of 10 mg (or 5 mg dependent on evaluation of Part A).
Study NCT01490476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: 10 mg per os / day or 05mg per os / day with 12 month
Study NCT01899794 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TVT-O/Oxytrol
Study NCT01899794 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TVT-O
Study NCT01899794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytrol
Study NCT02834208 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI (Magnetic resonance imaging)
Study NCT02834208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI (Magnetic resonance imaging)
Study NCT02834208 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Polymorphism (SNP in DNA)
Study NCT02834208 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Polymorphism (SNP in DNA)
Study NCT01755559 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Artesunate-amodiaquine
Description: antimalarial ACT
Study NCT01755559 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dihydroartemisinin-piperaquine
Description: antimalarial ACT
Study NCT02258516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHIME 3-M
Description: behavioral intervention for self-management in heart failure
Study NCT02258516 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: attention control
Description: patients will receive phone calls regarding health-related topics not associated with heart failure
Study NCT01158885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: 20 mg/m2/day intravenously (IV) over 2 hours (given at hours 0 to 2) on days 1 through 5.
Study NCT01158885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine intravenous
Description: 1 gram/m2/day intravenously (IV) over 2 hours to be given 4 hours after the initiation of clofarabine on days 1 through 5.
Study NCT01158885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate to be given intrathecally (IT) to all acute lymphoblastic leukemia (ALL) patients on day 1 at the dose defined by age below:~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients >9 years of age
Study NCT01158885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal (IT) Cytarabine
Description: Intrathecal (IT) cytarabine is optional for acute myelogenous leukemia (AML) patients.~If intrathecal cytarabine is to be given, it must be given at least 72 hours but not more than 7 days prior to the initiation of intravenous cytarabine.~Dose should be given according to age as defined below:~* 30 mg for patients age 1-1.99~* 50 mg for patients age 2-2.99~* 70 mg for patients >3 years of age
Study NCT01185613 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapy™ Cool Flex Ablation Catheter
Description: The device under evaluation is the 4mm Therapy™ Cool Flex Ablation Catheter. The Therapy™ Cool Flex catheter is a flexible tip, insulated, 7F catheter constructed of thermoplastic elastomer material and noble metal electrodes.~The following CE Mark devices will be used in conjunction with the Therapy™ Cool Flex Ablation Catheter~* IBI-1500T11 Cardiac Ablation Generator (RF ablation generator) with software version 3.0 or higher.~* Cool Point™ Irrigation Pump~* Cool Point™ Tubing set~* Data Logger
Study NCT03813576 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Self-collected HPV vaginal swab
Description: Patients will be instructed on how to collect a vaginal swab on themselves which will then be processed for presence of HPV DNA.
Study NCT03436992 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidant Cocktail
Description: Vitamin C, Vitamin E, alpha lipoic acid
Study NCT03436992 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: 1500 mg trans-resveratrol
Study NCT03436992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo
Study NCT01678794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan
Description: 4 mg once a day up to 13 day. dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated
Study NCT01678794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 mg once a day up to 13 day. dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated
Study NCT03142724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MNI-968
Description: Healthy volunteers recruited for the study will undergo a single \[18F\]MNI-968 injections and PET scans.
Study NCT01157585 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: paliperidone ER
Description: 8 week prospective study
Study NCT01533285 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo
Description: Placebo is Treatment A and C. Form=saline solution for intramuscular (IM) injection (Injection of a solution into a muscle), route = IM, Unit = mL, number = 0.5 administered on Day 1 of Period 1 and Period 2.
Study NCT01533285 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Salmonella typhi vaccine (Typhim Vi)
Description: Salmonella typhi vaccine (typhoid vaccination) in Treatment B and D; Unit = mg, number = 0.025, form = solution for intramuscularly (IM) injection, route = IM administered on Day 1 of Period 1 and Period 2.
Study NCT02785458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMC2 Strategy
Description: The intervention includes 1) distribution of simplified one-page medication guide summaries, 2) an automated follow-up call to assess medication safety and problematic side effects and 3) summary reports of call to providers with any concerns flagged for clinic follow-up.
Study NCT02100163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Hypnosis
Description: The patient receives virtual reality hypnosis daily.
Study NCT02100163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio Hypnosis
Description: Patient will listen to an Audio Hypnosis recording daily.
Study NCT02100163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment
Study NCT03128268 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imaging software for 4 dimensional images for Cardiac MRI
Description: All enrollees will receive Cardiac MRI scans using Imaging software for 4 dimensional images for Cardiac MRI
Study NCT01062841 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Targeted Infection Control
Description: Component 1: Institute enhanced barrier precautions for all NH residents with indwelling devices; active screening for MDROs (monthly) using cultures collected from multiple body sites to identify asymptomatic MDRO carriage in these residents; and dissemination of results to clinical staff and administration.~Component 2: Structured, active surveillance for infections using standardized definitions in residents with indwelling devices and dissemination of results to clinical staff and administration.~Component 3: A hand hygiene promotion program. Component 4: A structured educational program pertaining to indwelling device care for healthcare workers.
Study NCT01205802 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: MHV reconstruction
Description: MHV reconstruction with PTFE or homograft
Study NCT01205802 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MHV reconstruction
Description: MHV reconstruction with PTFE or homograft